209 related articles for article (PubMed ID: 26840260)
21. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.
Huang R; Mo D; Wu J; Ai H; Lu Y
Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis.
Madjd Z; Erfani E; Gheytanchi E; Moradi-Lakeh M; Shariftabrizi A; Asadi-Lari M
Int J Biol Markers; 2016 May; 31(2):e118-25. PubMed ID: 27102864
[TBL] [Abstract][Full Text] [Related]
23. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.
Zhang X; Hua R; Wang X; Huang M; Gan L; Wu Z; Zhang J; Wang H; Cheng Y; Li J; Guo W
Oncotarget; 2016 Mar; 7(9):9815-31. PubMed ID: 26769843
[TBL] [Abstract][Full Text] [Related]
24. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond.
Soleimani A; Dadjoo P; Avan A; Soleimanpour S; Rajabian M; Ferns G; Ryzhikov M; Khazaei M; Hassanian SM
Life Sci; 2022 Mar; 293():120050. PubMed ID: 35026215
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
[TBL] [Abstract][Full Text] [Related]
26. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
27. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
29. The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Eto S; Yoshikawa K; Shimada M; Higashijima J; Tokunaga T; Nakao T; Nishi M; Takasu C; Sato H; Kurita N
Anticancer Res; 2015 Apr; 35(4):2071-6. PubMed ID: 25862862
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
32. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
33. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of CD133 and ezrin expression in colorectal carcinoma.
Fathi A; Mosaad H; Hussein S; Roshdy M; Ismail EI
IUBMB Life; 2017 May; 69(5):328-340. PubMed ID: 28261953
[TBL] [Abstract][Full Text] [Related]
35. Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.
Zambo I; Hermanova M; Zapletalova D; Skoda J; Mudry P; Kyr M; Zitterbart K; Sterba J; Veselska R
Cancer Biomark; 2016 Jun; 17(1):107-16. PubMed ID: 27314299
[TBL] [Abstract][Full Text] [Related]
36. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
37. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
[TBL] [Abstract][Full Text] [Related]
38. Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma.
Lee YM; Yeo MK; Seong IO; Kim KH
Anticancer Res; 2018 Aug; 38(8):4819-4826. PubMed ID: 30061254
[TBL] [Abstract][Full Text] [Related]
39. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.
Chen S; Song X; Chen Z; Li X; Li M; Liu H; Li J
PLoS One; 2013; 8(2):e56380. PubMed ID: 23409180
[TBL] [Abstract][Full Text] [Related]
40. CD133 in brain tumor: the prognostic factor.
Li B; McCrudden CM; Yuen HF; Xi X; Lyu P; Chan KW; Zhang SD; Kwok HF
Oncotarget; 2017 Feb; 8(7):11144-11159. PubMed ID: 28055976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
